Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
138,100
Employees138,100
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
138,100
Employees138,100

JNJ Key Statistics

Market cap
374.84B
Market cap374.84B
Price-Earnings ratio
17.26
Price-Earnings ratio17.26
Dividend yield
3.23%
Dividend yield3.23%
Average volume
7.55M
Average volume7.55M
High today
$156.76
High today$156.76
Low today
$154.21
Low today$154.21
Open price
$154.40
Open price$154.40
Volume
6.44M
Volume6.44M
52 Week high
$169.99
52 Week high$169.99
52 Week low
$140.68
52 Week low$140.68

JNJ News

Simply Wall St 14h
Johnson & Johnson Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA

submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health p...

Johnson & Johnson Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA
TipRanks 19h
Johnson & Johnson submits sNDA to U.S FDA for CAPLYTA

Johnson & Johnson announced the submission of a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, based upon long-term dat...

TipRanks 1d
Nanobiotix announces regulatory harmonization, new patent for JNJ-1900

Nanobiotix (NBTX) announced two developments related to radioenhancer JNJ-1900, which is licensed by Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. H...

Analyst ratings

56%

of 25 ratings
Buy
44%
Hold
56%
Sell
0%

More JNJ News

TipRanks 2d
Balanced Outlook on Johnson & Johnson: MedTech Growth vs. Pharmaceutical Challenges

Analyst Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson and keeping the price target at $170.00. Don’t Miss TipRanks’ Half-Year...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.